VivoSeq
Other

Obese Patients

0

Pipeline Programs

7

Active Trials

9

Companies Involved

Obese Patients is an early-stage landscape with 0 programs across 9 companies. The most active players are Sanofi, Merck & Co., Pfizer.

Pipeline Metrics

Competitive Density

22/100

Pipeline Velocity

11/100

Mech. Concentration

N/A

Completion Rate

83/100

Attrition Rate

12/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Programs by Phase

No pipeline programs currently tracked for this disease.

Trial Status

65

clinical trials

Completed38 · 58%
Unknown status12 · 18%
Recruiting5 · 8%
Terminated5 · 8%
Withdrawn3 · 5%
Not yet recruiting1 · 2%
Other1 · 2%

Trial Activity

65 trials

Effect of Nicorandil in Type 2 Diabetic Obese Patients
Recruiting·TTanta University·Phase 2/3·NCT06423729·46 enrolled
Pharmacodynamic Trial on Rocuronium in Obese Patients
Completed··Phase 4·NCT00540085·51 enrolled
Effects of Anesthesia With Propofol Versus Desflurane in Obese Patients
Completed··Phase 4·NCT03417518·40 enrolled
Page 1 of 5

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)